These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. Peng SB; Henry JR; Kaufman MD; Lu WP; Smith BD; Vogeti S; Rutkoski TJ; Wise S; Chun L; Zhang Y; Van Horn RD; Yin T; Zhang X; Yadav V; Chen SH; Gong X; Ma X; Webster Y; Buchanan S; Mochalkin I; Huber L; Kays L; Donoho GP; Walgren J; McCann D; Patel P; Conti I; Plowman GD; Starling JJ; Flynn DL Cancer Cell; 2015 Sep; 28(3):384-98. PubMed ID: 26343583 [TBL] [Abstract][Full Text] [Related]
26. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2. Wen-Sheng W Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661 [TBL] [Abstract][Full Text] [Related]
27. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Balmanno K; Chell SD; Gillings AS; Hayat S; Cook SJ Int J Cancer; 2009 Nov; 125(10):2332-41. PubMed ID: 19637312 [TBL] [Abstract][Full Text] [Related]
28. Scaffolding mechanism of arrestin-2 in the cRaf/MEK1/ERK signaling cascade. Qu C; Park JY; Yun MW; He QT; Yang F; Kim K; Ham D; Li RR; Iverson TM; Gurevich VV; Sun JP; Chung KY Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34507982 [TBL] [Abstract][Full Text] [Related]
29. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Montagut C; Sharma SV; Shioda T; McDermott U; Ulman M; Ulkus LE; Dias-Santagata D; Stubbs H; Lee DY; Singh A; Drew L; Haber DA; Settleman J Cancer Res; 2008 Jun; 68(12):4853-61. PubMed ID: 18559533 [TBL] [Abstract][Full Text] [Related]
30. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities. Wang P; Laster K; Jia X; Dong Z; Liu K Mol Cancer; 2023 Dec; 22(1):208. PubMed ID: 38111008 [TBL] [Abstract][Full Text] [Related]
31. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238 [TBL] [Abstract][Full Text] [Related]
32. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors. Ming Z; Lim SY; Kefford RF; Rizos H Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489 [TBL] [Abstract][Full Text] [Related]
33. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755 [TBL] [Abstract][Full Text] [Related]
34. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation. Heard JJ; Phung I; Potes MI; Tamanoi F BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991 [TBL] [Abstract][Full Text] [Related]
35. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576 [TBL] [Abstract][Full Text] [Related]
36. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210 [TBL] [Abstract][Full Text] [Related]
37. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells. Henry JR; Kaufman MD; Peng SB; Ahn YM; Caldwell TM; Vogeti L; Telikepalli H; Lu WP; Hood MM; Rutkoski TJ; Smith BD; Vogeti S; Miller D; Wise SC; Chun L; Zhang X; Zhang Y; Kays L; Hipskind PA; Wrobleski AD; Lobb KL; Clay JM; Cohen JD; Walgren JL; McCann D; Patel P; Clawson DK; Guo S; Manglicmot D; Groshong C; Logan C; Starling JJ; Flynn DL J Med Chem; 2015 May; 58(10):4165-79. PubMed ID: 25965804 [TBL] [Abstract][Full Text] [Related]